Dysthyroid optic neuropathy
Thyroid eye disease · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Sight-threatening compression of the optic nerve at the orbital apex in thyroid eye disease (usually Graves), from enlarged extraocular muscles. Presents with reduced acuity, dyschromatopsia, a relative afferent pupillary defect and colour desaturation, often with proptosis and restricted eye movements.
Red flags
- Falling acuity or worsening colour vision
- New relative afferent pupillary defect
- Corneal breakdown
- Disc swelling with field loss
Assessment
Differential diagnosis
- Orbital cellulitis
- Optic neuritis
- Orbital tumour
- Idiopathic orbital inflammation
- Corneal exposure keratopathy (competing cause of visual loss)
Investigations
- Visual acuity, colour vision, relative afferent pupillary defect and visual fields
- CT/MRI orbits (apical crowding, muscle enlargement)
- Thyroid function and TSH receptor antibodies
- Intraocular pressure and corneal assessment
- Fundoscopy for disc swelling
Management
- Recognise reduced acuity, colour desaturation and an RAPD as sight-threatening compressive optic neuropathy
- Refer emergently to ophthalmology/oculoplastics and endocrinology
- Start high-dose IV corticosteroid to reduce inflammation and swelling
- Arrange urgent orbital decompression if steroids fail or vision is severely threatened
- Protect the cornea (lubrication, taping) and control thyroid status
- Advise strict smoking cessation (worsens the disease)
Drugs & doses
High-dose IV methylprednisolone (pulsed)
Corneal lubricants for exposure
Antithyroid therapy / control of thyroid status
Selenium and steroid-sparing agents in specialist care
Disposition
Emergency ophthalmology referral; admit for IV steroids +/- decompression.
Complications & pitfalls
- Permanent visual loss
- Corneal ulceration and perforation
- Diplopia
Exam pearls
- Colour desaturation and an RAPD, not proptosis severity, herald optic neuropathy - test them
- Smoking dramatically worsens thyroid eye disease; cessation is part of treatment
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.